trial

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

NCTId NCT04820309
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 566 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2024-05-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
566 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-06-02
Primary completion
2024-05-24
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Investigators

1
Inder Kaul, MDStudy Director

Sites

117 total
Little Rock, United StatesLittle Rock, United StatesRogers, United StatesRogers, United StatesAnaheim, United StatesAnaheim, United StatesBellflower, United StatesBellflower, United StatesBellflower, United StatesCerritos, United StatesCosta Mesa, United StatesCosta Mesa, United States

Linked catalysts

1
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy o — primary completion2024-05-24

Facts & assertions

4 sourced
Enrollment
566
Phase
PHASE3
Primary Completion Date
2024-05-24
Status
COMPLETED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Inder Kaul, MD
person